Skip to content

Author

E. Azhar

We have 8 of 97 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Fungal detection, diagnostic approaches, and antifungal susceptibility in diabetic foot ulcers: a systematic review of recent evidence

Background Fungal infections are an emerging but underrecognized concern in diabetic foot ulcers (DFU); and may contribute to delaying healing and complicate clinical outcomes. This study reviewed available evidence to identify the neglected contribution of fungi to DFUs and to explore their antifungal susceptibility p...

Salma M. Alsayed, A. Khateb, Muhammad Yasir et al. · 0 citations
Review Open access Sep 2026

MERS-CoV in Africa: a One Health review of the silent reservoir.

Africa harbours more than 80% of the world's dromedary camels, with a pooled MERS-CoV seroprevalence of 73·7%; however, no autochthonous outbreak in humans has been documented. In this Review, we weigh five interacting explanations for the absence of documented human outbreaks based on the strength of the evidence for...

Shreif A. El-Kafrawy, M. El-Daly, Menatalla S. El-Kafrawy et al. · 0 citations
Review Open access Aug 2026

MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.

Middle East respiratory syndrome coronavirus (MERS-CoV) remains a low-incidence but high-consequence zoonotic coronavirus threat. Since its identification in Saudi Arabia in 2012, more than 2600 laboratory-confirmed cases have been reported from 27 countries, most from the Arabian Peninsula; the reported case fatality...

E. Azhar, M. Alqahtani, A. Assiri et al. · 0 citations
#protein folding Review Open access Oct 2026

ORF2 of hepatitis E virus: genetic and antigenic variation across genotypes and implications for immunity, diagnostics and vaccine development

Abstract Hepatitis E virus (HEV) causes over 19 million infections annually, yet the molecular determinants governing its diverse clinical phenotypes and cross-genotype immunity remain incompletely synthesized. The ORF2 capsid protein is the sole structural component of the virion, the primary neutralizing antibody tar...

Shreif A. El-Kafrawy, S. S. Putra, A. Abbas et al. · 0 citations
Open access Sep 2026

From El Niño forecasts to proportionate public health action: a forecast-to-action framework for climate-related health risks

El Niño creates an important opportunity for anticipatory public health action because its development can often be detected before many downstream hazards emerge. Yet predictability does not transfer uniformly from the large-scale El Niño Southern Oscillation (ENSO) signal to regional climate anomalies and ultimately...

L. Bajrai, E. Azhar · 0 citations
Open access Aug 2026

Gene-environment interaction between VDR variants and vitamin D deficiency identifies a high-risk inflammatory phenotype associated with COVID-19 severity

Together, these findings identify a genetically associated inflammatory risk profile characterized by VDR risk alleles, vitamin D deficiency, and heightened inflammatory responses, providing a framework for precision risk stratification targeting the vitamin D-VDR axis.

HariOm Singh, Aishwarya Nair, Meenakshi Bhattacharya et al. · 0 citations
Review Open access Jul 2026

Durability of COVID-19 vaccine-induced immunity in Saudi Arabia: evidence, gaps, and implications for Hajj and mass-gathering preparedness

The review highlights those circulating antibodies and neutralizing activity decline after vaccination, particularly against antigenically divergent variants, whereas memory B-cell responses and CD4+ and CD8+ T-cell immunity generally provide more durable protection against severe disease.

Leena E. Azhar, Ahdab A. Alsaieedi, M. Al Eissa et al. · 0 citations
Review Open access Aug 2026

Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation

Host receptor targeting is a mechanistically rational but still clinically unproven component of the respiratory antiviral landscape; its value is most plausibly realised in defined niches—prophylaxis, early outpatient treatment, and combination with direct-acting antivirals—and within pandemic preparedness frameworks,...

S. El-Kafrawy, Norah A. Othman, M. Zeyadi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.